Novartis, a global healthcare company, is thriving with a 36.3% stock surge this year, supported by strong pipeline execution and new regulatory wins. The company will report Q3 earnings on Oct. 28, with net sales up 11% in Q2. CEO Vas Narasimhan highlighted the success of newer oncology, neurology, and cardiovascular products. Novartis recently gained FDA approval for Rhapsido for chronic spontaneous urticaria, costing $4,521 for 30 days. The company also signed a $5.7 billion deal with Monte Rosa Therapeutics and a $5.2 billion deal with Argo Biopharmaceutical, showing commitment to innovation. Analysts predict high single-digit sales growth for Novartis through 2025.

Read more at Yahoo Finance: Should You Buy Novartis Stock Before October 28?